SCHEMBL6901164

SCHEMBL6901164

CCCCOc1coc(C)cc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
CA9 Q16790 3/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA3 P07451 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6900182 0.79 RAB9A (0.42) CYP1A2CYP2C19RAB9ANPC1RECQL
SCHEMBL15883997 0.79 NPC1 (0.42) CYP1A2CYP2C19RAB9ANPC1RECQL
SCHEMBL6900551 0.79 RAB9A (0.58) KDM4ECYP1A2CYP2C19RAB9ANPC1
SCHEMBL6900481 0.78 MEN1 (0.42) CA9TSHRTP53ELANETDP1
SCHEMBL14136602 0.75 ELANE (0.44) CYP1A2CYP2C19RAB9ANPC1RECQL
SCHEMBL3395761 0.75 ELANE (0.59) KDM4ERAB9ANPC1RECQLELANE
SCHEMBL3022639 0.74 ELANE (0.61) RAB9ANPC1ELANESMN1; SMN2
SCHEMBL12723378 0.73 IDH1 (0.54) CYP1A2CYP2C19RAB9ANPC1RECQL
SCHEMBL8130917 0.73 RAB9A (0.56) KDM4ECYP1A2CYP2C19RAB9ANPC1
SCHEMBL8130837 0.73 RAB9A (0.56) KDM4ECYP1A2CYP2C19RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017156194-A1 COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-09-14 WO disclosed
US-9399651-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders Merck, Sharp & Dohme Corp. (US) 2016-07-26 US disclosed
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2015-10-22 US disclosed
US-9024032-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2015-05-05 US disclosed
US-20130084346-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-04-04 US disclosed
WO-2011109254-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT LMNA 3949/4885MAPT 220/4885NPSR1 3345/4885
US-20130084346-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT LMNA 3949/4885MAPT 220/4885NPSR1 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.